Aron Knickerbocker, CEO of Five Prime Therapeutics (NASDAQ: FPRX), has resigned “to pursue new challenges and opportunities,” the company announced after the market close Thursday. Knickerbocker was promoted to CEO nearly two years ago to succeed founder and longtime CEO Lewis “Rusty” Williams, who became the South San Francisco biotech’s executive chairman.
Five Prime said Thursday that board member William Ringo has been appointed interim CEO while the company searches for a permanent chief executive. Ringo has been a board member since 2014 and chairman of the board since January. Ringo’s experience includes serving as president and CEO of… Read more »
UNDERWRITERS AND PARTNERS
